Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition

References

• Abebe A, Demissie D, Goudsmit J, et al. (1999). HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13:1305–11
   PubMed Web of Science ®Google Scholar
• Agrawal-Gamse C, Lee FH, Haggarty B, et al. (2009). Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol 83:11005–15
   PubMed Web of Science ®Google Scholar
• Agrawal L, Maxwell CR, Peters PJ, et al. (2009). Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia. J Gen Virol 90:710–22
   PubMed Web of Science ®Google Scholar
• Alencar C, Nishiya A, Ferreira S, et al. (2010). Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations. AIDS Res Hum Retroviruses 26:1267–71
   PubMed Web of Science ®Google Scholar
• An P, Li R, Wang JM, Yoshimura T, et al. (2011). Role of exonic variation in chemokine receptor genes on AIDS: CCRL2 F167Y association with pneumocystis pneumonia. PLoS Genet 7:e1002328
   PubMedGoogle Scholar
• Ananworanich J, Schuetz A, Vandergeeten C, et al. (2012). Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PloS one 7:e33948
   PubMed Web of Science ®Google Scholar
• Andrianov A, Anishchenko I, Tuzikov A. (2011). Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop. J Chem Inf Model 51:2760–7
   PubMed Web of Science ®Google Scholar
• Armand-Ugón M, Moncunill G, Gonzalez E, et al. (2010). Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J Antimicrob Chemother 65:417–24
   PubMed Web of Science ®Google Scholar
• Baroncelli S, Galluzzo CM, Weimer LE, et al. (2012). Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. J Antimicrob Chemother 67:1479–85
   PubMed Web of Science ®Google Scholar
• Barouch DH, Klasse PJ, Dufour J, et al. (2012). Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 109:8694–8
   PubMed Web of Science ®Google Scholar
• Begaud E, Feindirongai G, Versmisse P, et al. (2003). Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic. AIDS Res Hum Retroviruses 19:551–60
   PubMed Web of Science ®Google Scholar
• Berger EA, Doms RW, Fenyö EM, et al. (1998). A new classification for HIV-1. Nature 391:240
   PubMed Web of Science ®Google Scholar
• Berro R, Klasse PJ, Lascano D, et al. (2011). Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol 85:8227–40
   PubMed Web of Science ®Google Scholar
• Björndal A, Sönnerborg A, Tscherning C, et al. (1999). Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 15:647–53
   PubMed Web of Science ®Google Scholar
• Bonjoch A, Pou C, Perez-Alvarez N, et al. (2013). Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J Antimicrob Chemother 68:1382–7
   PubMed Web of Science ®Google Scholar
• Briz V, Garcia D, Mendez-Lagares G, et al. (2012). High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission. Pediatr Infect Dis J 31:1048–52
   PubMed Web of Science ®Google Scholar
• Bronshtein T, Toledano N, Danino D, et al. (2011). Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells. J Control Release 151:139–48
   PubMed Web of Science ®Google Scholar
• Bunnik E, Quakkelaar E, van Nuenen A, et al. (2007). Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol 81:525–31
   PubMed Web of Science ®Google Scholar
• Cabral G, Ferreira J, Coelho L, et al. (2012). Concordance of HIV type 1 tropism phenotype to predictions using web-based analysis of V3 sequences: composite algorithms may be needed to properly assess viral tropism. AIDS Res Hum Retroviruses 28:734–8
   PubMed Web of Science ®Google Scholar
• Champagne P, Ogg GS, King AS, et al. (2001). Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106–11
   PubMed Web of Science ®Google Scholar
• Charpentier C, Joly V, Larrouy L, et al. (2013). Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. J Antimicrob Chemother 68:690–6
   PubMed Web of Science ®Google Scholar
• Chesebro B, Nishio J, Perryman S, et al. (1991). Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol 65:5782–9
   PubMed Web of Science ®Google Scholar
• Chong H, Yao X, Zhang C, et al. (2012). Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PloS one 7:e32599
   PubMed Web of Science ®Google Scholar
• Cilliers T, Willey S, Sullivan W, et al. (2005). Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virol 339:136–44
   PubMed Web of Science ®Google Scholar
• Coetzer M, Cilliers T, Ping L, et al. (2006). Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virol 356:95–105
   PubMed Web of Science ®Google Scholar
• Coetzer M, Nedellec R, Cilliers T, et al. (2011). Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr 56:9–15
   PubMed Web of Science ®Google Scholar
• Connell B, Michler K, Capovilla A, et al. (2008). Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 22:896–9
   PubMed Web of Science ®Google Scholar
• Connor R, Sheridan K, Ceradini D, et al. (1997). Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185:621–8
   PubMed Web of Science ®Google Scholar
• Cooper DA, Heera J, Goodrich J, et al. (2010). Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 201:803–13
   PubMed Web of Science ®Google Scholar
• Däumer M, Kaiser R, Klein R, et al. (2011). Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak 11:30
   PubMedGoogle Scholar
• De Jong J, De Ronde A, Keulen W, et al. (1992). Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66:6777–80
   PubMed Web of Science ®Google Scholar
• De Wolf F, Hogervorst E, Goudsmit J, et al. (1994). Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 10:1387–400
   PubMed Web of Science ®Google Scholar
• Dean M, Carrington M, Winkler C, et al. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856–62
   PubMed Web of Science ®Google Scholar
• Decker JM, Bibollet-Ruche F, Wei X, et al. (2005). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201:1407–19
   PubMed Web of Science ®Google Scholar
• Delgado E, Fernández-García A, Vega Y, et al. (2012). Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 67:25–31
   PubMed Web of Science ®Google Scholar
• Delmedico MK, Bray BL, Cammack N, et al. (2006). Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections, Abstract 48
   Google Scholar
• Demarest J, Amrine-Madsen H, Irlbeck D, et al. (2009). Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother 53:1116–23
   PubMed Web of Science ®Google Scholar
• Denizot M, Varbanov M, Espert L, et al. (2008). HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy 4:998–1008
   PubMed Web of Science ®Google Scholar
• Dervillez X, Klaukien V, Dürr R, et al. (2010). Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage. J Virol 84:10131–8
   PubMed Web of Science ®Google Scholar
• Dimonte S, Mercurio F, Svicher V, et al. (2011). Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v3 signatures in the regulation of co-receptor usage. Retrovirology 8:33
   PubMed Web of Science ®Google Scholar
• Duggal P, An P, Beaty TH, et al. (2003). Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun 4:245–50
   PubMed Web of Science ®Google Scholar
• Dumond JB, Patterson KB, Pecha AL, et al. (2009). Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 51:546–53
   PubMed Web of Science ®Google Scholar
• Esbjörnsson J, Månsson F, Martínez-Arias W, et al. (2010). Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease – indication of an evolving epidemic in West Africa. Retrovirology 7:23
   PubMedGoogle Scholar
• Fätkenheuer G, Nelson M, Lazzarin A, et al. (2008). Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359:1442–55
   PubMed Web of Science ®Google Scholar
• Ferain T, Hoveyda H, Ooms F, et al. (2011). Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther 337:655–62
   PubMed Web of Science ®Google Scholar
• Forbes CJ, Lowry D, Geer L, et al. (2011). Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 156:161–9
   PubMed Web of Science ®Google Scholar
• Forssmann WG, The YH, Stoll M, et al. (2010). Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Science Transl Med 2:63re3
   PubMedGoogle Scholar
• Fouchier RA, Groenink M, Kootstra NA, et al. (1992). Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66:3183–7
   PubMed Web of Science ®Google Scholar
• Frange P, Chaix ML, Raymond S, et al. (2010). Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol 48:3487–91
   PubMed Web of Science ®Google Scholar
• Gathe J, Diaz R, Fätkenheuer G, et al. (2010). Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. 17th Conference on Retroviruses and Opportunistic Infections, Abstract #54LB
   Google Scholar
• Genebat M, Ruiz-Mateos E, González-Serna A, et al. (2011). Discordance rates between Trofile test and short-term virological response to maraviroc. Antiviral Res 89:182–5
   PubMed Web of Science ®Google Scholar
• Genebat M, Ruiz-Mateos E, León JA, et al. (2009). Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother 64:845–9
   PubMed Web of Science ®Google Scholar
• Geretti AM, Harrison L, Green H, et al. (2009). Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 48:1296–305
   PubMed Web of Science ®Google Scholar
• Gharu L, Ringe R, Bhattacharya J. (2012). Evidence of extended alternate coreceptor usage by HIV-1 clade C envelope obtained from an Indian patient. Virus Res 163:410–14
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, McGovern RA, Harrigan PR, et al. (2012). Correlation of the virological response to short-term Maraviroc monotherapy with standard and deep sequencing-based genotypic tropism methods. Antimicrob Agents Chemother 56:1202–7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, Romero-Sanchez MC, Ferrando-Martinez S, et al. (2012). HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients. Antimicrob Agents Chemother 56:3981–3
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Ballana E, Clotet B, Este JA. (2011). Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS 25:1557–83
   PubMedGoogle Scholar
• Gonzalez S, Gondwe C, Tully DC, et al. (2010). Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia. AIDS Res Hum Retroviruses 26:795–803
   PubMed Web of Science ®Google Scholar
• Groenink M, Fouchier RA, Broersen S, et al. (1993). Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260:1513–16
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359:1429–41
   PubMed Web of Science ®Google Scholar
• Gutierrez C, Diaz L, Vallejo A, et al. (2011). Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PloS one 6:e27864
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Lalezari J, Hellinger JA, et al. (2011). Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother 55:722–8
   PubMed Web of Science ®Google Scholar
• Hardy WD, Gulick RM, Mayer H, et al. (2010). Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 55:558–64
   PubMed Web of Science ®Google Scholar
• Harrington R, Geballe A. (1993). Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol 67:5939–47
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier AC, Lederman MM, et al. (2004). Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37:1253–62
   PubMed Web of Science ®Google Scholar
• Hladik F, Sakchalathorn P, Ballweber L, et al. (2007). Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26:257–70
   PubMed Web of Science ®Google Scholar
• Hoffmann C. (2007). The epidemiology of HIV coreceptor tropism. Eur J Med Res 12:385–90
   PubMed Web of Science ®Google Scholar
• Hu Q, Huang X, Shattock R. (2010). C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. J Gen Virol 91:2965–73
   PubMed Web of Science ®Google Scholar
• Hu Q, Mahmood N, Shattock RJ. (2007). High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368:145–54
   PubMed Web of Science ®Google Scholar
• Huang W, Eshleman SH, Toma J, et al. (2007). Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 81:7885–93
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Rosenberg PS, Goedert JJ, et al. (2001). Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 135:782–95
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Lalezari JP, Thompson MA, et al. (2010a). Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 54:4137–42
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Saag MS, Thompson MA, et al. (2008). Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 198:1345–52
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Thompson MA, Lalezari JP, et al. (2010b). Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 201:1481–7
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Israel RJ, Lowy I, et al. (2004). Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 48:423–9
   PubMed Web of Science ®Google Scholar
• Jensen M, Coetzer M, van ‘t Wout A, et al. (2006). A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 80:4698–704
   PubMed Web of Science ®Google Scholar
• Jensen MA, Li FS, van ‘t Wout AB, et al. (2003). Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77:13376–88
   PubMed Web of Science ®Google Scholar
• Ji C, Zhang J, Dioszegi M, et al. (2007). CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol Pharmacol 72:18–28
   PubMed Web of Science ®Google Scholar
• Jiang S, Lin K, Strick N, Neurath A. (1993). HIV-1 inhibition by a peptide. Nature 365:113
   PubMed Web of Science ®Google Scholar
• Johnston E, Zijenah L, Mutetwa S, et al. (2003). High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 77:7682–8
   PubMed Web of Science ®Google Scholar
• Kagan RM, Johnson EP, Siaw M, et al. (2012). A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PloS one 7:e46334
   PubMedGoogle Scholar
• Kaleebu P, Nankya IL, Yirrell DL, et al. (2007). Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 45:28–33
   PubMed Web of Science ®Google Scholar
• Karlsson A, Parsmyr K, Aperia K, et al. (1994). MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J Infect Dis 170:1367–75
   PubMed Web of Science ®Google Scholar
• Karlsson U, Antonsson L, Ljungberg B, et al. (2012). Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. AIDS 26:1739–44
   PubMed Web of Science ®Google Scholar
• Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. (2008). Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105:7552–7
   PubMed Web of Science ®Google Scholar
• Khanlou H, Gathe J, Schrader S, et al. (2011). H2-794b – safety, efficacy, and pharmacokinetics of Ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago; American Society of Microbiology
   Google Scholar
• Klibanov O, Williams S, Iler C. (2010). Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Invest Drugs 11:940–50
   PubMed Web of Science ®Google Scholar
• Kondru R, Zhang J, Ji C, et al. (2008). Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 73:789–800
   PubMed Web of Science ®Google Scholar
• Koot M, Keet IP, Vos AH, et al. (1993). Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118:681–8
   PubMed Web of Science ®Google Scholar
• Koot M, Vos AH, Keet RP, et al. (1992). HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6:49–54
   PubMed Web of Science ®Google Scholar
• Kwong P, Wyatt R, Robinson J, et al. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648–59
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Poignard P, Raja A, et al. (2003). Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77:10557–65
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Angel JB, Hoffmann C, et al. (2008). Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 198:1113–22
   PubMed Web of Science ®Google Scholar
• Latinovic O, Reitz M, Le NM, et al. (2011). CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology 411:32–40
   PubMed Web of Science ®Google Scholar
• Lee C, Liu QH, Tomkowicz B, et al. (2003). Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. J Leukoc Biol 74:676–82
   PubMed Web of Science ®Google Scholar
• Lengauer T, Sander O, Sierra S, et al. (2007). Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 25:1407–10
   PubMed Web of Science ®Google Scholar
• Li Y, Han Y, Xie J, et al. (2013). CRF01_AE subtype is associated with faster disease progression in Chinese HIV-1 sexually infected patients. Proceedings of 20th Conference on Retroviruses and Opportunistic Infections. Available from: http://www.retroconference.org/2013b/abstracts/47040.htm [last accessed 15 Sep 2013]
   Google Scholar
• Liang B, Luo M, Scott-Herridge J, et al. (2011). A comparison of parallel pyrosequencing and sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1. PloS one 6:e26745
   PubMedGoogle Scholar
• Lifson JD, Feinberg MB, Reyes GR, et al. (1986). Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature 323:725–8
   PubMed Web of Science ®Google Scholar
• Lin NH, Negusse DM, Beroukhim R, et al. (2010). The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods 169:39–46
   PubMed Web of Science ®Google Scholar
• Locher CP, Witt SA, Kassel R, et al. (2005). Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation. J Gen Virol 86:1171–9
   PubMed Web of Science ®Google Scholar
• Long E, Rainwater S, Lavreys L, et al. (2002). HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18:567–76
   PubMed Web of Science ®Google Scholar
• Low A, Swenson L, Harrigan P. (2008). HIV coreceptor phenotyping in the clinical setting. AIDS Rev 10:143–51
   PubMed Web of Science ®Google Scholar
• Lusso P, Earl PL, Sironi F, et al. (2005). Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79:6957–68
   PubMed Web of Science ®Google Scholar
• Maeda K, Das D, Yin PD, et al. (2008). Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 381:956–74
   PubMed Web of Science ®Google Scholar
• Majetschak M. (2011). Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J Leukoc Biol 89:205–19
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Forbes CJ, Geer L, et al. (2013). Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 68:678–83
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Veazey RS, Geer L, et al. (2012). Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 56:2251–8
   PubMed Web of Science ®Google Scholar
• McGovern RA, Thielen A, Mo T, et al. (2010). Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24:2517–25
   PubMed Web of Science ®Google Scholar
• McGovern RA, Thielen A, Portsmouth S, et al. (2012). Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 61:279–86
   PubMed Web of Science ®Google Scholar
• Meini G, Rossetti B, Bianco C, et al. (2013). Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. J Antimicrob Chemother [Epub ahead of print]
   Google Scholar
• Metz M, Bourque E, Labrecque J, et al. (2011). Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach. J Am Chem Soc 133:16477–85
   PubMed Web of Science ®Google Scholar
• Mills A, Mildvan D, Podzamczer D, et al. (2013). Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr 62:164–70
   PubMed Web of Science ®Google Scholar
• Monno L, Saracino A, Scudeller L, et al. (2011). Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob Agents Chemother 55:5078–84
   PubMed Web of Science ®Google Scholar
• Moyle G, DeJesus E, Boffito M, et al. (2009). Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 48:798–805
   PubMed Web of Science ®Google Scholar
• Murphy PM, Baggiolini M, Charo IF, et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145–76
   PubMed Web of Science ®Google Scholar
• Murray EJ, Leaman DP, Pawa N, et al. (2010). A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J Virol 84:7288–99
   PubMed Web of Science ®Google Scholar
• Neff CP, Kurisu T, Ndolo T, et al. (2011). A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PloS one 6:e20209
   PubMed Web of Science ®Google Scholar
• Neff CP, Ndolo T, Tandon A, et al. (2010). Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PloS One 5:e15257
   PubMed Web of Science ®Google Scholar
• Nelson M, Arastéh K, Clotet B, et al. (2005). Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40:404–12
   PubMed Web of Science ®Google Scholar
• Nelson M, Panos G. (2007). Resistance to chemokine (C-C motif) receptor 5 antagonists. Euro Infect Dis 1:68–70
   Google Scholar
• Nettles RE, Schurmann D, Zhu L, et al. (2012). Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 206:1002–11
   PubMed Web of Science ®Google Scholar
• Nozza S, Galli L, Bigoloni A, et al. (2011). Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr 56:e113–15
   PubMed Web of Science ®Google Scholar
• Nozza S, Galli L, Visco F, et al. (2010). Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 24:924–8
   PubMed Web of Science ®Google Scholar
• Ogert RA, Wojcik L, Buontempo C, et al. (2008). Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373:387–99
   PubMed Web of Science ®Google Scholar
• Pace CS, Fordyce MW, Franco D, et al. (2013). Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 62:1–9
   PubMed Web of Science ®Google Scholar
• Panos G, Nelson M. (2007). HIV-1 tropism. Biomark Med 1:473–81
   PubMed Web of Science ®Google Scholar
• Panos G, Nelson M. (2008). Viral (HIV) entry: how does it work? In: Jäger H, ed. Entry inhibitoren. Berlin, Heidelberg: Springer, 3–10
   Google Scholar
• Peeters M, Vincent R, Perret J, et al. (1999). Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 20:115–21
   PubMedGoogle Scholar
• Peters PJ, Duenas-Decamp MJ, Sullivan WM, et al. (2008). Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 5:5
   PubMed Web of Science ®Google Scholar
• Pöhlmann S, Krumbiegel M, Kirchhoff F. (1999). Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1. J Gen Virol 80:1241–51
   PubMed Web of Science ®Google Scholar
• Pugach P, Marozsan A, Ketas T, et al. (2007). HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212–28
   PubMed Web of Science ®Google Scholar
• Putcharoen O, Lee SH, Henrich TJ, et al. (2012). HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol 86:1119–28
   PubMed Web of Science ®Google Scholar
• Ray N, Harrison JE, Blackburn LA, et al. (2007). Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 81:3240–50
   PubMed Web of Science ®Google Scholar
• Ray N, Hwang C, Healy MD, et al. (2013). Prediction of virologic response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr 64:7–15
   PubMed Web of Science ®Google Scholar
• Raymond S, Delobel P, Chaix ML, et al. (2011). Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 8:56
   PubMed Web of Science ®Google Scholar
• Raymond S, Delobel P, Mavigner M, et al. (2010). Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 47:126–30
   PubMed Web of Science ®Google Scholar
• Recordon-Pinson P, Soulié C, Flandre P, et al. (2010). Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 54:3335–40
   PubMed Web of Science ®Google Scholar
• Reeves JD, Lee FH, Miamidian JL, et al. (2005). Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79:4991–9
   PubMed Web of Science ®Google Scholar
• Richman D, Bozzette S. (1994). The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169:968–74
   PubMed Web of Science ®Google Scholar
• Rieder P, Joos B, Scherrer AU, et al. (2011). Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis 53:1271–9
   PubMed Web of Science ®Google Scholar
• Roche M, Jakobsen MR, Ellett A, et al. (2011). HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology 8:89
   PubMed Web of Science ®Google Scholar
• Roche M, Jakobsen MR, Sterjovski J, et al. (2011). HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol 85:4330–42
   PubMed Web of Science ®Google Scholar
• Rossi R, Lichtner M, De Rosa A, et al. (2011). In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 166:184–90
   PubMed Web of Science ®Google Scholar
• Ruiz-Mateos E, González-Serna A, Genebat M, et al. (2011). Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors. Antimicrob Agents Chemother 55:4664–9
   PubMed Web of Science ®Google Scholar
• Saag M, Goodrich J, Fätkenheuer G, et al. (2009). A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 199:1638–47
   PubMed Web of Science ®Google Scholar
• Salazar-Gonzalez JF, Bailes E, Pham KT, et al. (2008). Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82:3952–70
   PubMed Web of Science ®Google Scholar
• Saliou A, Delobel P, Dubois M, et al. (2011). Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 55:2831–6
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Mackay C, Lanzavecchia A. (1998). Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187:875–83
   PubMed Web of Science ®Google Scholar
• Samson M, Libert F, Doranz BJ, et al. (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722–5
   PubMed Web of Science ®Google Scholar
• Scarlatti G, Tresoldi E, Björndal A, et al. (1997). In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3:1259–65
   PubMed Web of Science ®Google Scholar
• Schuitemaker H, Koot M, Kootstra NA, et al. (1992). Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66:1354–60
   PubMed Web of Science ®Google Scholar
• Schuitemaker H, van't Wout A, Lusso P. (2011). Clinical significance of HIV-1 coreceptor usage. J Transl Med 9:S5
   PubMed Web of Science ®Google Scholar
• Seclén E, Garrido C, González Mdel M, et al. (2010). High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 65:1486–92
   PubMed Web of Science ®Google Scholar
• Seclén E, González Mdel M, Lapaz M, et al. (2010). Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. J Antimicrob Chemother 65:2502–4
   PubMed Web of Science ®Google Scholar
• Shioda T, Levy J, Cheng-Mayer C. (1992). Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89:9434–8
   PubMed Web of Science ®Google Scholar
• Shytaj IL, Norelli S, Chirullo B, et al. (2012). A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathogens 8:e1002774
   PubMedGoogle Scholar
• Simon B, Grabmeier-Pfistershammer K, Rieger A, et al. (2010). HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 24:2051–8
   PubMed Web of Science ®Google Scholar
• Stupple PA, Batchelor DV, Corless M, et al. (2011). An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-2 32798). J Med Chem 54:67–77
   PubMed Web of Science ®Google Scholar
• Svicher V, Alteri C, Artese A, et al. (2011). Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. Antivir Ther 16:1035–45
   PubMed Web of Science ®Google Scholar
• Svicher V, D'Arrigo R, Alteri C, et al. (2010). Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 33:195–206
   PubMed Web of Science ®Google Scholar
• Svicher V, Alteri C, Montano M, et al. (2013). Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection [Epub ahead of print]
   Google Scholar
• Swenson LC, Chui CK, Brumme CJ, et al. (2013). Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob Agents Chemother 57:6122–30
   Google Scholar
• Swenson LC, Mo T, Dong WW, et al. (2011). Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 203:237–45
   PubMed Web of Science ®Google Scholar
• Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR. (2011). Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 53:732–42
   PubMed Web of Science ®Google Scholar
• Symons J, Vandekerckhove L, Paredes R, et al. (2011). Impact of triplicate testing on genotypic HIV-1 tropism prediction in routine clinical practice. Clin Microbiol Infect 18:606–12
   PubMed Web of Science ®Google Scholar
• Tan L, Nelson M. (2008). Maraviroc: a CCR5 antagonist. Future HIV therapy 2:111–23
   Google Scholar
• Tebit D, Zekeng L, Kaptué L, et al. (2002). Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retroviruses 18:39–48
   PubMed Web of Science ®Google Scholar
• Tilton JC, Wilen CB, Didigu CA, et al. (2010). A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 84:10863–76
   PubMed Web of Science ®Google Scholar
• Tran EE, Borgnia MJ, Kuybeda O, et al. (2012). Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 8:e1002797
   PubMed Web of Science ®Google Scholar
• Trinh L, Han D, Huang W, et al. (2008). Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antivir Ther 13:A128
   Web of Science ®Google Scholar
• Tsamis F, Gavrilov S, Kajumo F, et al. (2003). Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77:5201–8
   PubMed Web of Science ®Google Scholar
• Tsibris AM, Korber B, Arnaout R, et al. (2009). Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PloS one 4:e5683
   PubMed Web of Science ®Google Scholar
• Tsibris AM, Hu Z, Paredes R, et al. (2012). Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol 86:6416–26
   PubMed Web of Science ®Google Scholar
• Tsibris AM, Pal U, Schure AL, et al. (2011). SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PloS one 6:e28047
   PubMedGoogle Scholar
• van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. (1994). Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 94:2060–7
   PubMed Web of Science ®Google Scholar
• Vandekerckhove LP, Wensing AM, Kaiser R, et al. (2011). European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11:394–407
   PubMed Web of Science ®Google Scholar
• Veazey RS, Ketas TJ, Dufour J, et al. (2010). Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 202:739–44
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Brudney D, Reynaerts J, et al. (2011). Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 12:544–52
   PubMed Web of Science ®Google Scholar
• Vitiello P, Brudney D, MacCartney M, et al. (2012). Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Intervirology 55:172–8
   PubMed Web of Science ®Google Scholar
• Watson C, Jenkinson S, Kazmierski W, Kenakin T. (2005). The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67:1268–82
   PubMed Web of Science ®Google Scholar
• Westby M, Lewis M, Whitcomb J, et al. (2006). Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80:4909–20
   PubMed Web of Science ®Google Scholar
• Westby M, Smith-Burchnell C, Mori J, et al. (2007). Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81:2359–71
   PubMed Web of Science ®Google Scholar
• Westrop SJ, Moyle GJ, Imami N. (2010). Nature and function of CCR5 in immune activation, HIV-1 entry, and targeted therapeutics. J Viral Entry 4:1–10
   Google Scholar
• Westrop SJ, Moyle G, Jackson A, et al. (2012). CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection. Mol Med 18:1240–8
   PubMed Web of Science ®Google Scholar
• Whitcomb JM, Huang W, Fransen S, et al. (2007). Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51:566–75
   PubMed Web of Science ®Google Scholar
• Wong R, Bodart V, Metz M, et al. (2008). Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74:1485–95
   PubMed Web of Science ®Google Scholar
• Wu L, LaRosa G, Kassam N, et al. (1997). Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186:1373–81
   PubMed Web of Science ®Google Scholar
• Xie D, Yao C, Wang L, et al. (2010). An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54:191–6
   PubMed Web of Science ®Google Scholar
• Xiong S, Fan J, Kitazato K. (2010). The antiviral protein cyanovirin-N: the current state of its production and applications. Appl Microbiol Biotechnol 86:805–12
   PubMed Web of Science ®Google Scholar
• Yoshie O. (2000). Immune chemokines and their receptors: the key elements in the genesis, homeostasis and function of the immune system. Springer Semin Immunopathol 22:371–91
   PubMed Web of Science ®Google Scholar
• Yu XF, Wang Z, Beyrer C, et al. (1995). Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol 69:4649–55
   PubMed Web of Science ®Google Scholar
• Yu X, Yuan L, Huang Y, et al. (2011). Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. PloS one 6:e17605
   PubMedGoogle Scholar
• Yuan Y, Maeda Y, Terasawa H, et al. (2011). A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 413:293–9
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Dragic T, Cao Y, et al. (1998). Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 72:9337–44
   PubMed Web of Science ®Google Scholar
• Zhong P, Burda S, Konings F, et al. (2003). Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses 19:1167–78
   PubMed Web of Science ®Google Scholar
• Zhu P, Olson WC, Roux KH. (2001). Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J Virol 75:6682–6
   PubMed Web of Science ®Google Scholar
• Zhu T, Mo H, Wang N, et al. (1993). Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179–81
   PubMed Web of Science ®Google Scholar